Among them, AZD9291 is the only one recently approved by FDA for the treatment of advanced NSCLC patients with EGFR mutations and shows 200-fold selectivity for T790M/L858R double mutants over wild type (WT) EGFR (Cross et al., 2014; Jiang and Zhou, 2014). Here, EGFR is linked to non-small cell lung carcinoma.